Continuing with a growth-by-acquisition theme, Genzyme Corp. late Thursday unveiled plans for a $1 billion stock purchase of cancer drug developer ILEX Oncology Inc. (BioWorld Today)

Continuing with a growth-by-acquisition theme, Genzyme Corp. late Thursday unveiled plans for a $1 billion stock purchase of cancer drug developer ILEX Oncology Inc. (BioWorld Today)

Genentech Inc.'s Avastin received FDA approval as a first-line treatment in metastatic colorectal cancer. With the company saying it will launch the product into the eager arms of patients and doctors within three days and sales expectations high, the drug seems bound for biotechnology folklore. (BioWorld Today)